Compliance with the document of the spanish society of nephrology 2002 document for the control of diabetic nephropathy in catalonia (ECCODIAB);Estudio sobre el grado de cumplimiento ambulatorio del documento de consenso 2002 para el control de la nefropatía diabética en Cataluña (ECCODIAB)

Nefrologia

Volumn 26, Issue 6, 2006, Pages 679-687

  Fontseré, Néstor ^a   Bonal, J ^b   Torres, F ^c   De Las Cuevas, X ^a   Fort, J ^d  

^a HOSPITAL DE TERRASSA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

2002 diabetes consensus document; Blood pressure; Diabetic patients; Glycated hemoglobin; Lipidic control; Nephroprotection

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CREATININE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; ARTICLE; BLOOD; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CLASSIFICATION; CLINICAL TRIAL; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MEDICAL SOCIETY; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; SMOKING CESSATION; SPAIN; STATISTICS; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COMORBIDITY; CREATININE; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; GUIDELINE ADHERENCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; SMOKING CESSATION; SOCIETIES, MEDICAL; SPAIN; TREATMENT REFUSAL;

EID: 34147118009     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. st century: diabetes mellitus. Lancet 356: 757-761, 2000.
2. Wild et al.: Global prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 27(5): 1047-1053, 2004.
3. Catalonia registry: Department of public health. Barcelona 2004. (http://www.ocatt.net/).
4. 2002 consensus document about the detection, prevention and treatment of diabetic nephropathy in Spain. Nefrología 22 (6): 521-530, 2002.
5. American Diabetes Association: Clinical practice recommendations. Diabetes Care Supl. 1: S1-S70, 1997.
6. Levey AS, Greene T, Kusek J, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11: A0828, 2000.
7. Levey AS, Coresh J, Balk E et al.: National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, Classification and Stratification. Ann Intern Med 139: 137-147, 2003.
8. Fagerudd J, Forsblom C, Pettersson-Fernholm K, Groop PH for the Finn Diane Study Group. Implementation of Guidelines for the Prevention of Diabetic Nephropathy. Diabetes Care 27 (3): 803-804, 2004.
9. Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM: Diabetic nephropathy: how effective is treatment in clinical practice? Q J Med 95: 41-49, 2002.
10. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. Br Med J 317: 713-720, 1998.
11. Stamler J, Vaccaro O, Neaton J, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. diabetes Care 16: 434-449, 1993.
12. Ruggenanti P, Gambara V, Perra A: The nephropathy in non-insulin dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 9: 2336-2343, 1998.
13. Stehouwer CD, Nauta JJ, Zeldenrust GC, Macking WH, Donker AJ, Den Ottolander GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340: 319-323, 1992.
14. Calviño J, Calvo C, Romero R, Gude F, Sánchez-Gorsande D: Atherosclerosis profile and microalbuminuria in essential hypertension. Am J Kidney Dis 34: 996-1001, 1999.
15. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 803: 81-87, 1991.
16. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: 601-606, 2000.
17. Romero R, Salinas I, Lucas A, Abad E: Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensine-converting enzyme inhibitors. Diabetes Care 16: 597-600, 1993.
18. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 349: 1787-1792, 1997.
19. Ravid M, Brosh D, Levi Z et al.: Use of enalapril to atenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128: 982-988, 1998.
20. Lewis EJ, Hunsicker LG, Brain RP, Rohde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993.
21. Parving HH, Lehnert H, Brochner-Mortensen J et al.: The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
22. Yokoyama H, Tomanaga O, Hirayama M, Ishii A, Takeda M, Babazono T, Ujihara U, Takahashi C, Omari Y: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetología 40: 405-411, 1997.
23. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
24. Brenner BM, Cooper ME, De Zeeuw D et al.: Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-878, 2001.
25. Rossing P, Hougaard P, Parving HH: Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int 68: 1446-1450, 2005.
26. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. Br Med J 317: 713-720, 1998.
27. Hanson L, Lindholm LH, Niskanen L et al.: Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 353: 611-616, 1999.
28. Yusuf S, Sleight P, Pogue J, Bosh J, Davies R, Dagenais G: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153, 2000.
29. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338: 645-652, 1998.
30. Staessen JA, Thijsl, Gasowski J, Cells H, Fagard RH: Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur trial). Am J Cardiol 82(9B): 20-22, 1998.
31. Tatti, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21(4): 597-603, 1998.
32. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000.
33. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Juliuis S y cols., for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755-1762, 1998.
34. Martínez-Castelao A, Górriz JL, De Álvaro F et al.: Influence of an early treatment of anemia with r-Hu-EPO alfa on the quality of life and nephropathy progression in type 2 diabetes mellitus patients (EPODIAB study). JASN 15: A865-A866, 2004.
35. Orth SR, Schroeder T, Ritz E, Ferrari P: Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. Nephrol Dial Transplant 20 (11): 2414-2419, 2005.
36. Frimat L, Loos-Ayav C, Panescu V, Cordebar N, Briancon S, Kessler M: Early referral to a nephrologist is associated with better outcomes in type 2 diabetes patients with end-stage renal disease. Diabetes Metab 30(1): 67-74, 2004.